Blood Reviews
Volume 22, Issue 1 , Pages 33-52 , January 2008

Fetal and neonatal alloimmune thrombocytopenia: progress and ongoing debates

References 

  1. Burrows RF, Kelton JG. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. N Engl J Med. 1993;329:1463–1466
  2. Kjeldsen-Kraghl J, Killie MK, Aune B, et al. An intervention program for reducing morbidity and mortality associated with neonatal and allo-immune thrombocytopenia purpura (NAITP). Presented at the 8th European Symposium on Platelet and Granulocyte Immunobiology 2004; Rust, Australia.
  3. Turner ML, Bessos H, Fagge T, et al. Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a. Transfusion. 2005;45(12):1945–1956
  4. von dem Borne AEG, Decary F. Nomenclature of platelet-specific antigens. Transfusion. 1990;30:477–481
  5. Kelton JG, Smith JW, Horsewood P, et al. ABH antigens on human platelets: expression on the glycosyl phosphatidylinositol-anchored protein CD109. J Lab Clin Med. 1998;132:142–148
  6. Sharon R, Amar A. Maternal anti-HLA antibodies and neonatal thrombocytopenia. Lancet. 1981;1(8233):1313
  7. King KE, Kao KJ, Bray PF, et al. The role of HLA antibodies in neonatal thrombocytopenia: a prospective study. Tissue antigens. 1996;47:206–211
  8. Han KS, Song EY, Park MH. Neonatal alloimmune thrombocytopenia due to HLA antibodies. International Journal of Hematology 2002; 76 (suppl) 1:361–3.
  9. Saito S, Ota M, Komatsu Y, et al. Serologic analysis of three cases of neonatal alloimmune thrombocytopenia associated with HLA antibodies. Transfusion. 2003;43(7):908–917
  10. Moncharmont P, Dubois V, Obegi C, et al. HLA antibodies and neonatal alloimmune thrombocytopenia. Acta Haematol. 2004;111(4):215–220
  11. von dem Borne AEG, Decary F. ICSH/ISBT Working Party on Platelet Serology. Nomenclature of platelet-specific antigens. Vox Sang. 1990;58:176–177
  12. Kunicki TJ, Newman PJ. The molecular immunology of human platelet proteins. Blood. 1992;1386–1404
  13. Skupski DW, Bussel JB. Alloimmune thrombocytopenia. Clin Obstet Gynecol. 1999;42:335–348
  14. Newman PJ. Nomenclature of human platelet alloantigens: a problem with the HPA system?. Blood. 1994;83:1447–1451
  15. Blanchette VS, Petes MA, Pegg-Feige K. Alloimmune thrombocytopenia. Curr Stud Hematol Blood Transfus. 1988;55:87–96
  16. Mueller-Eckhardt C, Kiefel V, Grubert A, et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet. 1989;1:363–366
  17. Hohlfeld P, Forestier F, Kaplan C, Tissot JD, Daffos F. Fetal thrombocytopenia: a retrospective survey of 5194 fetal blood samplings. Blood. 1995;84:1851–1856
  18. Taaning E, Peterson S, Reinholdt J, et al. Neonatal immune thrombocytopenia due to allo- or antoantibodies. Platelets. 1994;5:53–58
  19. Bonacossa IA, Jocelyn LJ. Alloimmune thrombocytopenia of the newborn: neurodevelopmental sequele. Am J Perinatol. 1996;13:211–215
  20. Uhrynowska M, Maslanka K, Zupanska B. Neonatal thrombocytopenia: incidence, serological and clinical observations. Am J Perinatol. 1997;14:4154–4418
  21. Williamson LM, Hackett G, Rennie J, et al. The natural history of fetomaternal alloimmunization to the platelet–specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening. Blood. 1998;92:2280–2287
  22. Jægtvik S, Husebekk A, Aune B, Oian P, Dahl LB, Skogen B. Neonatal alloimmune thrombocytopenia due to anti-HPA-1a antibodies; the level of maternal antibodies predicts the severity of thrombocytopenia in the newborn. BJOG. 2000;107:691–694
  23. Uhrynowska M, Niznikowska_Marks M, Zupanska B. Neonatal and maternal thrombocytopenia: incidence and immune background. Eur J Haematol. 2000;64:42–46
  24. Kaplan C, Morel-Kopp C, Kroll H, et al. HPA-5b (Bra) neonatal alloimmune thrombocytopenia: clinical and immunological analysis of 39 cases. Br J Haematol. 1991;78:425–429
  25. Panzer S, Auerbach L, Cechova E, et al. Maternal alloimmunization against fetal platelet antigens: A prospective study. Br J Haematol. 1995;90:655–660
  26. Kurz M, Stöckelle B, Eichelberger B, Panzar S. IgG titer, subclass and light-chain phenotype of pregnancy-induced HPA-5b antibodies that cause or do not cause alloimmune thrombocytopenia. Transfusion. 1999;39:379–382
  27. Rousseau J, Goldman M, David M. HPA-5b (Bra) neonatal alloimmune thrombocytopenia in Quebec: incidence and clinical outcome in 31 cases. Transfusion. 2004;44(6):363–365
  28. Glade-Bender J, McFarland JG, Kaplan C, Porcelijn L, Bussel JB. Anti-HPA-3A induces severe neonatal alloimmune thrombocytopenia. J Pediatr. 2001;138(6):862–867
  29. Harrison CR, Curtis BR, McFarland JG, Huff RW, Aster RH. Severe neonatal alloimmune thrombocytopenia caused by antibodies to human platelet antigen 3a (Baka) detectable only in whole platelet assays. Transfusion. 2003;43(10):1398–1402
  30. Peterson JA, Balthazor SM, Curtis BR, McFarland JG, Aster RH. Maternal alloimmunization against the rare platelet-specific antigen HPA-9b (Max a) is an important cause of neonatal alloimmune thromobocytopenia. Transfusion. 2005;45(9):1487–1495
  31. Kaplan C, Porcelijn L, Vanlieferinghen P, et al. Anti-HPA-9bw (Maxa) fetomaternal alloimmunization, a clinically severe neonatal thrombocytopenia: difficulties in diagnosis and therapy and report on eight families. Transfusion. 2005;45(11):1799–1803
  32. Ertel K, Al-Tawil M, Santoso S, Kroll H. Relevance of the HPA-15 (Gov) polymorphism on CD109 in alloimmune thrombocypenic syndromes. Transfusion. 2005;45(3):366–373
  33. Curtis BR, Ali S, Glazier AM, Ebert DD, Aitman T, Aster RH. Isoimmunization against CD36 (glycoprotein IV): description of four cases of neonatal isoimmune thrombocytopenia and brief review of the literature. Transfusion. 2002;42(9):1173–1179
  34. Okajima S, Cho K, Chiba H, et al. Two sibling cases of hydrops fetalis due to alloimmune anti-DB36 (Nak a) antibody. J Thromb Haemost. 2006;95(2):267–271
  35. Gruel Y, Biozard B, Daffos F, Forestier F, Caen J, Wautier JL. Determination of platelet antigens and glycoproteins in the human fetus. Blood. 1986;68:488–492
  36. Giovangrandi Y, Daffos F, Kaplan C, Forestier F, Macaleese J, Moirot M. Very early intracranial Hemorrhage in alloimmune fetal thrombocytopenia. Lancet. 1990;336:310
  37. Murphy MF, Metcalfe P, Waters AH, Ord J, Hambley H, Nicolaides K. Antenatal management of severe feto-maternal thrombocytopenia: HLA incompatability may affect responses to fetal platelet transfusions. Blood. 1993;81:2174–2179
  38. Bessos H, Turner M, Urbaniak SJ. Is there a relationship between anti-HPA-1a concentration and severity of neonatal alloimmune thrombocytopenia?. Immunohematol. 2005;21(3):102–109
  39. Bertrand G, Martageix C, Jallu V, Vitry F, Kaplan C. Predictive value of sequential maternal anti-HPA-1a antibody concentrations for the severity of fetal alloimmune thrombocytopenia. J Thromb Haemost. 2006;4(3):628–637
  40. Killie MK, Husebekk A, Kaplan C, Taaning E, Skogen B. Maternal human platelet antigen-1a antibody level correlates with the platelet count in the newborns: a retrospective study. Transfusion. 2007;47(1):55–58
  41. van Loghem JJ, Dorfmeyer H, van der Hart M, Schreider F. Serological and genetical studies on a platelet antigen (Zw). Vox Sang. 1959;4:161–169
  42. Schulman NR, Marder VJ, Heller MC, Collier EM. Platelet and leukocyte isoantigens and their antibodies: serologic, physiologic, and clinical studies. Prog Hematol. 1964;4:222–304
  43. Flug F, Karpatkin M, Karaptkin S. Should all pregnant women be tested for their platelet PLA (Zw, HPA-1) phenotype?. Br J Haematol. 1994;86:1–5
  44. Blanchette VS, Chen L, Freidberg ZS, Hogan VA, Trudel E, Decary F. Alloimmunization to the PLA1 platelet antigen: results of a prospective study. Br J Haematol. 1990;74:209–215
  45. Durand-Zaleski I, Schlegel N, Blum-Boisgard C, Uzan S, Dreyfus M, Kaplan C. Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: A prospective comparison of effectiveness and costs. Am J Perinatol. 1996;13:423–431
  46. Reznikoff-Etievant MF, Dangu C, Lobet R. HLA-B8 antigen and anti-PlA1 alloimmunization. Tissue Antigens. 1981;18:66–68
  47. Mueller-Eckhardt C, Mueller_Eckhardt G, Willen-Ohff H, Horz H, Kuenzhen E, O’Neill GJ. Immunogenicity of an immune response to the platelet antigen Zw(a) is strongly associated with HLA-B8 and DR3. Tissue Antigens. 1985;26:71–76
  48. Mueller-Eckhardt C. HLA-B8 antigen and anti-PlA1 alloimmunization. Tissue Antigens. 1982;19:154–156
  49. Taaning E, Antosen H, Petersen S, Svejgaard A, Thomsen M. HLA antigens and maternal antibodies in allo-immune neonatal thrombocytopenia. Tissue Antigens. 1983;21:351–359
  50. Decary F. Is HLA-DR3 a risk factor in PLA1-negative pregnant women?. Curr Stud Hematol Blood Transfus. 1986;52:78–86
  51. Valentin N, Vergracht A, Bignon JD, et al. HLA-DRw52a is involved in alloimmunization against PLA1 antigen. Hum Immunol. 1990;27:73–79
  52. Decary F, L’Abbé D, Tremblay L, Chartrand P. The immune response to the HPA-1a antigen: association with HLA-DRw52a. Transfus Med. 1991;1:55–62
  53. L’Abbé D, Tremblay L, Filion M, et al. Alloimmunization to platelet antigen HPA-1a (PlA1) is strongly associated with both HLA-DRB3∗0101 and HLA-DQB1∗0201. Hum Immunol. 1992;34:107–114
  54. de Waal LP, van Dalen CM, Engelfreit CP, von dem Borne AEG. Alloimmunization against the platelet specific Zwa antigen, resulting in neonatal alloimmune thrombocytopenia or post-transfusion purpura, is associated with supertypic DRw52 antigen including DR3 and DRw6. Hum Immunol. 1986;4:222–304
  55. Wu S, Maslanka K, Gorski J. An integrin polymorphism that defines reactivity with alloantibodies generates an anchor for MHC class II peptide binding. J Immunol. 1997;158:3221–3226
  56. Mueller-Eckhardt C, Becker T, Weisheit M, Witz C, Santoso S. Neonatal alloimmune thrombocytopenia due to fetomaternal Zwb incompatibility. Vox Sang. 1986;50:94–96
  57. Westman P, Hashemi-Tavoularis S, Blanchette V, et al. Maternal DRB1∗1501, DQA1∗0102, DQB1∗0602 haplotype in fetomaternal alloimmunisation against human platelet alloantigen HPA-6B (GPIIIa-Gln489). Tissue Antigens. 1997;50:113–118
  58. Bussel JB, Zabusky MR, Berkowitz RL, McFarland JG. Fetal alloimmune thrombocytopenia. N Engl J Med. 1997;337(1):22–26
  59. Dreyfus M, Kaplan C, Verdy E, Schlegel N, Durant-Zaleski I, Tchernia G. The Immune Thrombocytopenia Working Group. Frequency of immune thrombocytopenia in newborns: A prospective study. Blood. 1997;89:4402–4406
  60. Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest. 1987;80(1):33–40
  61. Gernsheimer T, Stratton J, Ballem PJ, Slichter SJ. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. N Engl J Med. 1989;320(15):974–980
  62. Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, et al. AMG531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006;355(16):1672–1681
  63. Mueller-Eckhardt C, Marks H-J, Baur MP, Mueller_Eckhardt G. Immunogenic studies of the platelet-specific PlA1 (Zwa). Immunobiology. 1982;160:375–381
  64. Sainio S, Järvenpää A, Renlund M, Riikoren S, Teramo K, Kekomaki R. Thrombocytopenia in term children: a population based study. Obstet Gynecol. 2000;95:441–446
  65. Bussel JB, Zacharoulis S, Kramer K, McFarland JG, Pauliny J, Kaplan C. Clinical and diagnostic comparison of neonatal alloimmune thrombocytopenia to non-immune cases of thrombocytopenia. Pediatr Blood Cancer. 2005;45(2):176–183
  66. Birchall JE, Murphy MF, Kaplan C, Kroll H. European Fetomaternal Alloimmune Thrombocytopenic Study Group. European collaborative study of the antenatal management of feto-maternal alloimmune thrombocytopenia. Br J Haematol. 2003;122(2):275–288
  67. Berkowitz RL, Kolb EA, McFarland JG, et al. Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. Obstet Gynecol. 2006;107(1):91–96
  68. Berkowitz RL, Bussel JB, McFarland JG. Alloimmune thrombocytopenia: state of the art 2006. American Journal of Obstet Gynecol. 2006;195(4):907–913
  69. de Moerloose P, Boehlen F, Exterman P, Hohlfeld P. Neonatal thrombocytopenia: incidence and characterization of maternal antiplatelet antibodies by MAIPA assay. Br J Haematol. 1998;100:735–740
  70. Bussel JB, Berkowitz RL, Lynch L, et al. Antenatal management of alloimmune thrombocytopenia: a randomized trial in fifty-five maternal-fetal pairs. Am J Obstet Gynecol. 1996;174:1414–1423
  71. Pearson HA, Shulman NR, Marder VJ, Cone TE. Isoimmune neonatal thrombocytopenia purpura: Clinical and therapeutic considerations. Blood. 1964;23:154–157
  72. Chaoying M, Junwu G, Chituwo BM. Intraventricular hemorrhage and its prognosis, prevention and treatment in term infants. J Trop Pediatr. 1999;45:237–240
  73. Naidu S, Messmore H, Caserta V, Fine M. CNS lesions in neonatal isoimmune thrombocytopenia. Arch Neurol. 1983;40:552–554
  74. Dean LM, McLeary M, Taylor GA. Cerebral hemorrhage in alloimmune thrombocytopenia. Pediatr Radiol. 1995;25:444–445
  75. Johnson JA, Ryan G, al Mussa A, Farkus S, Blanchette US. Fetal diagnosis and management of neonatal alloimmune thrombocytopenia. Semin Perinatol. 1997;21:45–52
  76. Sherer DM, Anyaegbunam A, Onyeije C. Antepartum fetal intracranial hemorrhage, predisposing factors and prenatal sonography: a review. Am J Perinatol. 1998;7:431–441
  77. Dale ST, Coleman LT. Neonatal alloimmune thrombocytopenia: antenatal and postnatal imaging findings in the pediatric brain. Am J Neuroradiol. 2002;23(9):1457–1465
  78. Bussel JB, Tanli S, Peterson HC. Favorable neurological outcome in seven cases of perinatal intracranial hemorrhage due to immune thrombocytopenia. Am J Pediatr Hematol Oncol. 1991;13:156–159
  79. Khouzami AN, Kickler TS, Callan NA, Schuman JB, Perlman EJ, Blakemore KJ. Devastating sequelae of alloimmune thrombocytopenia: an entity that deserves more attention. J Matern Fetal Med. 1996;5:137–141
  80. Murphy MF, Hambley H, Nicolaides K, Waters AH. Severe fetomaternal alloimmune thrombocytopenia presenting with fetal hydrocephalus. Prenat Diagn. 1996;16:1152–1155
  81. Zalneraitis EL, Young RSK, Krishnamoorthy KS. Intracranial hemorrhage in utero as a complication of isoimmune thrombocytopenia. J Pediatr. 1979;95:611–614
  82. Herman JH, Jumbelic MI, Ancona RJ, Kickler TS. In utero cerebral hemorrhage in alloimmune thrombocytopenia. Am J Pediatr Hematol Oncol. 1986;8:312–317
  83. Morales WJ, Stroup M. Intracranial hemorrhage in utero due to isoimmune neonatal thrombocytopenia. Obstet Gynecol. 1985;65(suppl):20–21
  84. Friedman JM, Aster RH. Neonatal alloimmune thrombocytopenic purpura and congenital porencephaly in two siblings associated with a “new” maternal antiplatelet antibody. Blood. 1985;65:1412–1415
  85. Jesurun CA, Levin GS, Sullivan WR, Stevens D. Intracranial hemorrhage in utero re. Thrombocytopenia [Letter]. J Pediatr. 1980;97:695–696
  86. Meyer M, Kirchmaier CM, Schirmer A, Spangenberg P, Strohl C, Breddin K. Acquired disorder of platelet function associated with autoantibodies against membrane glycoprotein Iib-IIIa complex. Thromb Haemost. 1991;65:491–496
  87. Davoren A, Bussel J, Curtis BR, Moghaddam M, Aster RH, McFarland JG. Prospective evaluation of a new platelet glycoprotein (GP)-specific assay (PakAuto) in the diagnosis of autoimmune thrombocytopenia (AITP). Am J Hematol. 2005;78(3):193–197
  88. Beadling WV, Herman JH, Stuart MJ, Keashen-Schnell M, Miller JL. Fetal bleeding in neonatal alloimmune thrombocytopenia mediated by anti-PLA1 is not associated with inhibition of fibrinogen binding to platelet GPIIb/IIIa. Am J Clin Pathol. 1995;103:636–641
  89. Radder CM, Beekhuizen H, Kanhai HH, Brand A. Effect of maternal anti-HPA-1a antibodies and polyclonal IVIG on the activation status of vascular endothelial cells. Clin Exp Immunol. 2004;137(1):216–222
  90. Proulx C, Filion M, Goldman M, et al. Analysis of immunoglobulin class, IgG subclass and titre of HPA-1a antibodies in alloimmunized mothers giving birth to babies with or without neonatal alloimmune thrombocytopenia. Br J Haematol. 1994;87:813–817
  91. Weiner MF, Williamson LM, Rodeck CH. Immunoglobulin G subclass of anti-human platelet antigen 1a in maternal sera: relation to the severity of neonatal alloimmune thrombocytopenia. Eur J Haematol. 1997;59:287–292
  92. McFarland JG, Aster RH, Bussel JB, Gianopoulos JG, Derbes RS, Newman RJ. Prenatal diagnosis of neonatal alloimmune thrombocytopenia using allele-specific oligonucleotide probes. Blood. 1991;78:2276–2282
  93. Skogen B, Bellissimo DB, Hessner MJ, et al. Rapid determination of platelet alloantigen genotyped by polymerase chain reaction using allele-specific primers. Transfusion. 1994;34:955–960
  94. Avent ND. Antenatal genotyping of the blood groups of the fetus. Vox Sang. 1998;74(Suppl. 2):365–374
  95. Hughes D, Hurd C, Williamson LM. Genotyping for human platelet antigen-1 directly from dried blood spots on cards. Blood. 1996;88:3242–3243
  96. Bessos H, Mirza S, McGill A, Williamson LM, Hatfield R, Murphy WG. A whole blood assay for platelet HPA-1 (PLA1) phenotyping applicable to large scale antenatal screening. Br J Haematol. 1996;92:221–225
  97. Bessos H, Hofner M, Salamat A, Wilson D, Urbaniak S, Turner ML. An international trial demonstrates suitability of a newly developed whole-blood ELISA kit from multicentre platelet HPA-1 phenotyping. Vox Sang. 1999;77:103–106
  98. Quintanat A, Jallu V, Legros Y, Kaplan C. Human platelet antigen genotyping using a fluorescent SSCP technique with an automatic sequencer. British Journal of Haematology. 1998;103:437–444
  99. Kiefel V, Santoso S, Weishert M, Mueller-Eckhardt C. Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood. 1987;70:1722–1726
  100. Morel-Kopp MC, Kaplan C. Modification of the MAIPA technique to detect and identify anti-platelet glycoprotein auto-antibodies. Platelets. 1994;5:285
  101. Jousti L, Kekomäki R. Comparison of the direct platelet immunoflurescence test (direct PIFT) with a modified direct monoclonal antibody-specific immobilization of platelet antigens (direct MAIPA) in detection of platelet-associated IgG. Br J Haematol. 1997;96:204–209
  102. Dawkins B. Monitoring anti-HPA-1a platelet antibody levels during pregnancy using the MAIPA test. Vox Sang. 1995;68:27–34
  103. Metcalf P, Doughty HA, Murphy MF, Waters AH. A simplified method for large-scale HPA-1a phenotyping for antenatal screening. Transfus Med. 1994;4:21–25
  104. Bussel JB. Identifying babies with neonatal alloimmune thrombocytopenia and the responsible antigens. Transfusion. 2007;47(1):6–7
  105. Paidas MJ, Berkowitz RL, et al. Alloimmune thrombocytopenia: fetal and neonatal losses related to cordocentesis. Am J Obstet Gynecol. 1995;172(2 Pt1):475–479
  106. Ward MJ, Pauliny J, Lipper EG, Bussel JB. Long-term effects of fetal and neonatal alloimmune thrombocytopenia and its antenatal treatment on the medical and developmental outcomes of affected children. Am J Perinatol. 2006;23(8):487–492
  107. Sitarz AL, Driscoll JM, Wolff JA. Management of isoimmune neonatal thrombocytopenia. Am J Obstet Gynecol. 1976;124:39–42
  108. Murray JM, Harris RE. The management of the pregnant patient with idiopathic thrombocytopenic purpura. Am J Obstet Gynecol. 1976;126:449–451
  109. Sia CG, Amigo NC, Harper RG, Farahani G. Failure of cesarean section to prevent intracranial hemorrhage in siblings with isoimmune thrombocytopenia. Am J Obstet Gynecol. 1985;153:79–81
  110. Cook RL, Miller R, Katz VL, Cefalo RC. Immune thrombocytopenic purpura in pregnancy: a reappraisal of management. Obstet Gynecol. 1991;78:578–583
  111. Buscaglia M, Ghisoni L, Bellotti M, et al. Percutaneous umbilical blood sampling: indication changes and procedure loss rate in a nine years’ experience. Fetal Diagn Ther. 1996;11:106–113
  112. Petrikovsky B, Schneider EP, Klein VR, Wyse LJ. Cordocentesis using the combined technique: needle guide-assisted and free-hand. Fetal Diagn Ther. 1997;12:252–254
  113. Antsaklis A, Daskalakis G, Papantoniou N, Michalas S. Fetal blood sampling—indication-related losses. Prenat Diagn. 1998;18:934–940
  114. Tongsong T, Wanapirak C, Kunavikatikul C, Sirichotiyakul S, Piyamongkol W, Chanprapaph P. Cordocentesis at 16–24 weeks of gestation: experience of 1.320 cases. Prenat Diagn. 2000;20:224–228
  115. Pielet BW, Socol ML, MacGregor SN, Ney JA, Dooley SL. Cordocentesis: an appraisal of risks. Am J Obstet Gynecol. 1988;159:1497–1500
  116. Overton TG, Duncan KR, Jolly M, Letsky E, Fisk NM. Serial aggressive platelet transfusion for fetal alloimmune thrombocytopenia: platelet dynamics and perinatal outcome. Am J Obstet Gynecol. 2002;186:826–831
  117. Radder CM, Brand A, Kanhai HH. Will it ever be possible to balance the risk of intracranial hemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it?. Vox Sang. 2003;84(4):318–325
  118. Yinon Y, Spira M, Solomon O, et al. Antenatal noninvasive treatment of patients at risk for alloimmune thrombocytopenia without a history of intracranial hemorrhage. Am J Obstet Gynecol. 2006;195(4):1153–1157
  119. Paternoster DM, Cester M, Memmo A, Scandellari R, Fabris F, Girolami A. The management of feto-maternal alloimmune thrombocytopenia: report of three cases. J Matern Fetal Neonatal Med. 2006;19(8):517–520
  120. Radder CM, Brand A, Kanhai HH. A less invasive treatment strategy to prevent intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol. 2001;185(3):683–688
  121. Kanhai KK, van den Akker ES, Walther FJ, Brand A. Intravenous immunoglobulins without initial and follow-up cordocentesis in alloimmune fetal and neonatal thrombocytopenia at high risk for intracranial hemorrhage. Fetal Diagn Ther. 2006;21(1):55–60
  122. Gaddipati S, Berkowitz RL, Lembet AA, Lapinski R, McFarland JG, Bussel JB. Initial fetal platelet counts predict the response to intravenous gammaglobulin therapy in fetuses that are affected by PLA1 incompatibility. Am J Obstet Gynecol. 2001;185(4):976–980
  123. Bussel JB, Berkowitz RL, McFarland JG, Lynch L, Chitkara U. Antenatal treatment of neonatal alloimmune thrombocytopenia. N Engl J Med. 1988;319:1374–1378
  124. Lynch L, Bussel JB, McFarland JG, Chitkara U, Berkowitz RL. Antenatal treatment of alloimmune thrombocytopenia. Obstet and Gynecol. 1992;80:67–71
  125. Mir N, Samson D, House MJ, Kovar IZ. Failure of antenatal high-dose immunoglobulin to improve fetal platelet count in neonatal alloimmune thrombocytopenia. Vox Sang. 1988;55:188–189
  126. Nicolini U, Tannirandorn Y, Gonzalez P, et al. Continuing controversy in alloimmune thrombocytopenia: fetal hyperimmunoglobulin fails to prevent thrombocytopenia. Am J Obstet Gynecol. 1990;163:1144–1146
  127. Kroll H, Kiefel V, Griers G, et al. Maternal intravenous immunoglobulin treatment does not prevent intracranial hemorrhage in fetal alloimmune thrombocytopenia. Transfus Med. 1994;4:293–296
  128. Daffos R, Forestier F, Muller JY, et al. Prenatal treatment of alloimmune thrombocytopenia. Lancet. 1984;2:632
  129. Kaplan C, Forestier F, Cox WL, Lyon-Caen D, Dupuy-Montburn MC, Salmon C. Management of alloimmune thrombocytopenia: antenatal diagnosis and in utero transfusion of maternal platelets. Blood. 1988;72:340–343
  130. Nicolini U, Rodeck CH, Kochenour NK, Grenco P, Fisk NM, Letsky E. In utero platelet transfusion for alloimmune thrombocytopenia [Letter]. Lancet. 1988;2:506
  131. Murphy MF, Waters AH, Doughty HA, et al. Antenatal management of fetomaternal alloimmune thrombocytopenia-report of 15 affected pregnancies. Transfus Med. 1994;4:281–292
  132. Kaplan C, Murphy MK, Kroll H, Waters AH. Feto-maternal alloimmune thrombocytopenia: antenatal therapy with IvIgG and steroids–more questions than answers. European Working Group on FMAIT. Br J Haematol. 1998;100(1):62–65
  133. Radder CM, de Haan MJ, Brand A, Stoelhorst GM, Veen S, Kanhai HH. Follow up of children after antenatal treatment for alloimmune thrombocytopenia. Early Hum Dev. 2004;80(1):65–76
  134. Radder CM, Roelen DL, van de Meer-Prins EM, Claas FH, Kanhai KK, Brand A. The immunologic profile of infants born after maternal immunoglobulin treatment and intrauterine platelet transfusions for fetal/neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol. 2004;191(3):815–820
  135. Porcelijn L, Folman CC, de Haas M, et al. Fetal and neonatal thrombopoietin levels in alloimmune thrombocytopenia. Pediatr Res. 2002;52(1):105–108
  136. Cremer M, Dame C, Schaeffer HJ, Giers G, Bartmann P, Bald F. Longitudinal thrombopoietin plasma concentrations in fetuses with alloiumune thrombocytopenia treated with intrauterine PLT transfusions. Transfusion. 2003;43(9):1216–1222
  137. Adner MM, Fisch GR, Starobin SG, Aster RH. Use of “compatible” platelet transfusions in treatment of congenital isoimmune thrombocytopenic prupura. N Engl J Med. 1969;280:244–247
  138. Kiefel V, Bassler D, Kroll H, et al. Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT). Blood. 2006;107(9):3761–3763
  139. Murphy MF, Bussel JB. Advances in the management of alloimmune thrombocytopenia. Br J Haematol. 2007;136(3):366–378
  140. Bussel JB. When are platelets just platelets?. Blood. 2006;107(9):3426–3427
  141. Allen DL, Samol J, Benjamin S, Verjee S, Tusold A, Murphy MF. Survey of the use and clinical effectiveness of HPA-1a/5b-negative platelet concentrates in proven or suspected platelet alloimmunization. Transfus Med. 2004;14(6):409–417
  142. Sidiropoulos D, Straume B. The treatment of neonatal isoimmune thrombocytopenia with intravenous immunoglobin (IgG i.v.). Blut. 1984;48:383–386
  143. Derycke M, Dreyfus M, Ropert JC, Tchermia G. Intravenous immunoglobulin for neonatal isoimmune thrombocytopenia. Arch Dis Child. 1985;60:667–669
  144. Massey GV, McWilliams NB, Mueller DG, Napolitano A, Maurer HM. Intravenous immunoglobulin in neonatal isoimmune thrombocytopenia. J Pediatr. 1987;111:133–135
  145. Bussel JB, Kaplan C, McFarland J. Working Party on Neonatal Immune Thrombocytopenia of the Neonatal Hemostasis Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis: Recommendations for the evaluation and treatment of neonatal autoimmune and alloimmune thrombocytopenia. Thromb and Haemost. 1991;65:631–634
  146. Maslanka K, Lucas GF, Gonkowska A, Davis JG, Zupanska B. A second case of neonatal alloimmune thrombocytopenia associated with anti-PLA2 (Zwb) antibodies. Haematologia. 1989;22:109–113
  147. Kuijpers RW, van den Anker JN, Baerts W, von dem Borne AEG. A case of severe neonatal thrombocytopenia with schizencephaly associated with anti-HPA-1b and antiHPA-2a. Br J Haematol. 1994;87:576–579
  148. Mercier P, Chichepostiche C, Reviron D, Dabanian , Bourgue F, Chiarone J, et al. Neonatal thrombocytopenia in HLA-DR, -DQ, -DP-typed mother due to rare anti-HPA-1b (anti-PLA2) (Zwb) fetomaternal immunization. Vox Sang. 1994;67:45–51
  149. von den Anker J, Huiskes E, Porcelein L, von dem Bourne AE. Anti-HPA-1b really causes neonatal alloimmune thrombocytopenia. Br J Haematol. 1995;89:428
  150. Winters JL, Jennings CD, Desai NS. Neonatal alloimmune thrombocytopenia due to anti-HPA-1b (PLA2) (Zwb). Vox Sang. 1998;74:256–259
  151. von dem Borne AEG, von Riesz LE, Verheught FWA, ten Cate JAW, Koppe JG, Engelfriet LP. Baka, a new platelet-specific antigen involved in neonatal allo-immune thrombocytopenia. Vox Sang. 1980;39:113–120
  152. Kiefel V, Santoso S, Katxman B, Meuller-Eckhardt C. A new platelet-specific alloantigen Br(a): Report of 4 cases with neonatal alloimmune thrombocytopenia. Vox Sang. 1988;54:101–106
  153. Kekomäki R, Jouhikainen T, Ollikainen J, Westman P, Laes M. A new platelet alloantigen Tua, on glycoprotein IIIa associated with neonatal alloimmune thrombocytopenia in two families. Br J Haematol. 1993;83:306–310
  154. McFarland JG, Blanchette V, Collins J, Newman PJ, Wang R, Aster RH. Neonatal alloimmune thrombocytopenia due to a new platelet-specific alloantibody. Blood. 1993;81:3318–3323

PII: S0268-960X(07)00053-7

doi: 10.1016/j.blre.2007.09.002

Blood Reviews
Volume 22, Issue 1 , Pages 33-52 , January 2008

Article Tools